| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Wound Healing | 25 | 2023 | 482 | 5.420 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 26 | 2025 | 400 | 4.130 |
Why?
|
| Interleukin-10 | 12 | 2023 | 186 | 3.730 |
Why?
|
| Biomedical Research | 13 | 2023 | 560 | 3.390 |
Why?
|
| Surgeons | 9 | 2023 | 288 | 2.670 |
Why?
|
| Hyaluronic Acid | 11 | 2021 | 108 | 2.520 |
Why?
|
| Cicatrix | 6 | 2023 | 124 | 2.430 |
Why?
|
| Lung | 21 | 2025 | 1531 | 1.990 |
Why?
|
| Fetus | 13 | 2025 | 566 | 1.910 |
Why?
|
| Skin | 8 | 2023 | 536 | 1.710 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 3 | 2024 | 95 | 1.700 |
Why?
|
| Respiratory System Abnormalities | 8 | 2024 | 42 | 1.670 |
Why?
|
| Gene Transfer Techniques | 10 | 2015 | 344 | 1.610 |
Why?
|
| Fibroblasts | 5 | 2020 | 852 | 1.540 |
Why?
|
| Neovascularization, Physiologic | 8 | 2022 | 195 | 1.480 |
Why?
|
| Awards and Prizes | 3 | 2023 | 62 | 1.470 |
Why?
|
| Career Mobility | 3 | 2021 | 51 | 1.430 |
Why?
|
| Writing | 3 | 2021 | 59 | 1.430 |
Why?
|
| Extracellular Matrix | 9 | 2026 | 232 | 1.370 |
Why?
|
| Ultrasonography, Prenatal | 18 | 2025 | 973 | 1.350 |
Why?
|
| Fetoscopy | 12 | 2024 | 469 | 1.350 |
Why?
|
| Extracorporeal Membrane Oxygenation | 8 | 2024 | 674 | 1.340 |
Why?
|
| Endocardium | 3 | 2026 | 46 | 1.330 |
Why?
|
| Wounds and Injuries | 6 | 2020 | 391 | 1.310 |
Why?
|
| Intestines | 3 | 2021 | 587 | 1.280 |
Why?
|
| Phenyl Ethers | 3 | 2025 | 12 | 1.270 |
Why?
|
| Prenatal Diagnosis | 13 | 2024 | 615 | 1.230 |
Why?
|
| Endothelial Cells | 4 | 2026 | 521 | 1.210 |
Why?
|
| Pregnancy | 52 | 2025 | 7412 | 1.170 |
Why?
|
| Trachea | 9 | 2024 | 206 | 1.160 |
Why?
|
| Stress, Mechanical | 4 | 2026 | 178 | 1.160 |
Why?
|
| Fetal Development | 3 | 2015 | 126 | 1.120 |
Why?
|
| Infant, Newborn | 45 | 2025 | 8517 | 1.100 |
Why?
|
| Hypertension, Pulmonary | 5 | 2025 | 450 | 1.100 |
Why?
|
| Surgical Wound Infection | 2 | 2020 | 265 | 1.090 |
Why?
|
| Mentors | 3 | 2021 | 168 | 1.080 |
Why?
|
| Research Support as Topic | 2 | 2021 | 62 | 1.060 |
Why?
|
| Discrete Subaortic Stenosis | 2 | 2024 | 7 | 1.040 |
Why?
|
| National Institutes of Health (U.S.) | 4 | 2023 | 136 | 1.020 |
Why?
|
| Financing, Organized | 3 | 2022 | 21 | 1.010 |
Why?
|
| General Surgery | 4 | 2025 | 225 | 1.000 |
Why?
|
| Teratoma | 8 | 2024 | 120 | 0.980 |
Why?
|
| Gestational Age | 11 | 2025 | 1211 | 0.970 |
Why?
|
| Genetic Therapy | 4 | 2015 | 714 | 0.960 |
Why?
|
| Humans | 120 | 2026 | 130275 | 0.940 |
Why?
|
| Pediatrics | 5 | 2025 | 1243 | 0.910 |
Why?
|
| Inflammation | 6 | 2025 | 1481 | 0.890 |
Why?
|
| Bioprinting | 1 | 2024 | 13 | 0.870 |
Why?
|
| Spheroids, Cellular | 1 | 2024 | 59 | 0.860 |
Why?
|
| Hyaluronoglucosaminidase | 2 | 2021 | 27 | 0.850 |
Why?
|
| Gastroschisis | 2 | 2021 | 57 | 0.840 |
Why?
|
| Wound Infection | 4 | 2022 | 56 | 0.820 |
Why?
|
| Kidney | 3 | 2021 | 1278 | 0.820 |
Why?
|
| Animals | 45 | 2026 | 33777 | 0.810 |
Why?
|
| STAT3 Transcription Factor | 3 | 2022 | 228 | 0.810 |
Why?
|
| Hydrops Fetalis | 3 | 2020 | 83 | 0.800 |
Why?
|
| Retrospective Studies | 54 | 2025 | 17507 | 0.790 |
Why?
|
| Fetal Therapies | 3 | 2018 | 95 | 0.780 |
Why?
|
| Lung Diseases | 6 | 2023 | 396 | 0.780 |
Why?
|
| Genetic Vectors | 5 | 2013 | 895 | 0.780 |
Why?
|
| Bandages | 2 | 2020 | 52 | 0.770 |
Why?
|
| Dependovirus | 3 | 2013 | 160 | 0.760 |
Why?
|
| Female | 80 | 2026 | 70278 | 0.760 |
Why?
|
| Obstetric Labor, Premature | 1 | 2023 | 76 | 0.750 |
Why?
|
| Cystic Fibrosis | 3 | 2012 | 265 | 0.750 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2015 | 321 | 0.740 |
Why?
|
| Cell Survival | 1 | 2024 | 831 | 0.730 |
Why?
|
| Transplantation, Heterologous | 3 | 2012 | 256 | 0.720 |
Why?
|
| Actins | 1 | 2024 | 314 | 0.720 |
Why?
|
| Mice | 34 | 2026 | 18194 | 0.710 |
Why?
|
| Pulmonary Fibrosis | 2 | 2020 | 113 | 0.710 |
Why?
|
| Molecular Weight | 3 | 2021 | 277 | 0.710 |
Why?
|
| Dermis | 1 | 2021 | 25 | 0.700 |
Why?
|
| Abdominal Wall | 1 | 2021 | 26 | 0.700 |
Why?
|
| Budgets | 1 | 2021 | 15 | 0.690 |
Why?
|
| Cells, Cultured | 9 | 2025 | 2897 | 0.680 |
Why?
|
| Adenoviridae | 6 | 2015 | 582 | 0.680 |
Why?
|
| Disease Models, Animal | 11 | 2026 | 4659 | 0.670 |
Why?
|
| Congenital Abnormalities | 4 | 2025 | 322 | 0.670 |
Why?
|
| Mice, Inbred C57BL | 20 | 2025 | 4711 | 0.660 |
Why?
|
| Perinatal Care | 2 | 2022 | 65 | 0.660 |
Why?
|
| Efficiency | 2 | 2025 | 74 | 0.650 |
Why?
|
| Endothelial Progenitor Cells | 2 | 2022 | 10 | 0.650 |
Why?
|
| Skin Care | 1 | 2020 | 14 | 0.650 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2020 | 49 | 0.640 |
Why?
|
| Gastrostomy | 2 | 2020 | 83 | 0.630 |
Why?
|
| Dermatologic Agents | 1 | 2020 | 28 | 0.630 |
Why?
|
| Debridement | 1 | 2020 | 86 | 0.620 |
Why?
|
| Time-to-Treatment | 2 | 2018 | 210 | 0.620 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2022 | 331 | 0.610 |
Why?
|
| Emergency Treatment | 1 | 2020 | 82 | 0.610 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 278 | 0.600 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2021 | 499 | 0.600 |
Why?
|
| Length of Stay | 11 | 2025 | 1395 | 0.590 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2020 | 193 | 0.590 |
Why?
|
| Science | 1 | 2019 | 36 | 0.590 |
Why?
|
| Academies and Institutes | 1 | 2019 | 81 | 0.570 |
Why?
|
| Fetal Growth Retardation | 2 | 2025 | 253 | 0.570 |
Why?
|
| Heart Defects, Congenital | 4 | 2024 | 1867 | 0.570 |
Why?
|
| Fetal Diseases | 8 | 2024 | 440 | 0.570 |
Why?
|
| Periodicals as Topic | 1 | 2021 | 182 | 0.560 |
Why?
|
| Sacrococcygeal Region | 5 | 2024 | 36 | 0.550 |
Why?
|
| Herniorrhaphy | 1 | 2018 | 72 | 0.550 |
Why?
|
| Heart Transplantation | 1 | 2024 | 830 | 0.530 |
Why?
|
| Intensive Care Units, Pediatric | 3 | 2019 | 493 | 0.510 |
Why?
|
| Cytokines | 5 | 2025 | 1341 | 0.500 |
Why?
|
| Pandemics | 2 | 2021 | 1160 | 0.490 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2015 | 139 | 0.470 |
Why?
|
| Angiopoietin-1 | 1 | 2015 | 7 | 0.470 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2015 | 19 | 0.460 |
Why?
|
| Pseudomonas Infections | 3 | 2022 | 117 | 0.450 |
Why?
|
| Placental Insufficiency | 1 | 2015 | 14 | 0.450 |
Why?
|
| Myocardium | 1 | 2020 | 860 | 0.440 |
Why?
|
| Prenatal Care | 5 | 2025 | 346 | 0.430 |
Why?
|
| Algorithms | 2 | 2022 | 1660 | 0.420 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1290 | 0.420 |
Why?
|
| Placenta | 3 | 2023 | 500 | 0.420 |
Why?
|
| Infant | 21 | 2025 | 13223 | 0.420 |
Why?
|
| Education, Medical, Continuing | 1 | 2015 | 131 | 0.410 |
Why?
|
| Skin Physiological Phenomena | 2 | 2013 | 15 | 0.410 |
Why?
|
| Postoperative Complications | 4 | 2020 | 3115 | 0.400 |
Why?
|
| Gallbladder | 1 | 2013 | 19 | 0.400 |
Why?
|
| Cholecystitis | 1 | 2013 | 20 | 0.400 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 1712 | 0.400 |
Why?
|
| National Library of Medicine (U.S.) | 1 | 2013 | 3 | 0.400 |
Why?
|
| Palate | 1 | 2013 | 19 | 0.400 |
Why?
|
| Mouth Mucosa | 1 | 2013 | 46 | 0.390 |
Why?
|
| Cystic Adenomatoid Malformation of Lung, Congenital | 3 | 2022 | 18 | 0.390 |
Why?
|
| Male | 36 | 2026 | 64362 | 0.380 |
Why?
|
| Efficiency, Organizational | 2 | 2025 | 55 | 0.380 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 2 | 2011 | 48 | 0.380 |
Why?
|
| Alkaline Phosphatase | 1 | 2013 | 94 | 0.380 |
Why?
|
| Pressure Ulcer | 1 | 2013 | 69 | 0.380 |
Why?
|
| Cytomegalovirus | 1 | 2014 | 257 | 0.370 |
Why?
|
| Saliva | 1 | 2013 | 125 | 0.370 |
Why?
|
| Parvoviridae Infections | 1 | 2012 | 35 | 0.370 |
Why?
|
| United States | 9 | 2023 | 11840 | 0.370 |
Why?
|
| Viral Proteins | 1 | 2014 | 338 | 0.360 |
Why?
|
| Viral Tropism | 1 | 2012 | 55 | 0.350 |
Why?
|
| Immune Tolerance | 3 | 2019 | 155 | 0.350 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2013 | 208 | 0.340 |
Why?
|
| Exocrine Glands | 1 | 2011 | 6 | 0.340 |
Why?
|
| Lung Volume Measurements | 4 | 2025 | 73 | 0.330 |
Why?
|
| Research Personnel | 4 | 2022 | 141 | 0.330 |
Why?
|
| Airway Obstruction | 2 | 2023 | 173 | 0.320 |
Why?
|
| Pneumonectomy | 2 | 2018 | 153 | 0.320 |
Why?
|
| Treatment Outcome | 17 | 2024 | 12834 | 0.320 |
Why?
|
| Child Development | 1 | 2013 | 268 | 0.320 |
Why?
|
| Keratinocytes | 3 | 2016 | 73 | 0.310 |
Why?
|
| Macrophages | 3 | 2024 | 661 | 0.310 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2024 | 3744 | 0.310 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2013 | 255 | 0.310 |
Why?
|
| Hymecromone | 2 | 2021 | 10 | 0.300 |
Why?
|
| Pelvic Neoplasms | 2 | 2022 | 22 | 0.280 |
Why?
|
| Vagina | 2 | 2020 | 205 | 0.280 |
Why?
|
| Signal Transduction | 2 | 2020 | 4675 | 0.270 |
Why?
|
| Echocardiography | 3 | 2019 | 1127 | 0.270 |
Why?
|
| Spinal Neoplasms | 2 | 2022 | 78 | 0.270 |
Why?
|
| Clinical Competence | 1 | 2015 | 1064 | 0.270 |
Why?
|
| Hospitals, Pediatric | 4 | 2025 | 797 | 0.260 |
Why?
|
| Quality Improvement | 1 | 2013 | 705 | 0.250 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2024 | 23 | 0.250 |
Why?
|
| Organ Culture Techniques | 3 | 2014 | 140 | 0.250 |
Why?
|
| Cell Movement | 3 | 2015 | 868 | 0.250 |
Why?
|
| Mice, SCID | 2 | 2021 | 584 | 0.240 |
Why?
|
| Anxiety | 2 | 2023 | 1007 | 0.240 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2019 | 785 | 0.240 |
Why?
|
| Hirschsprung Disease | 1 | 2026 | 38 | 0.230 |
Why?
|
| Child | 16 | 2025 | 26072 | 0.230 |
Why?
|
| Abortion, Legal | 1 | 2025 | 18 | 0.230 |
Why?
|
| Fibrosis | 3 | 2026 | 418 | 0.230 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2021 | 289 | 0.220 |
Why?
|
| Heart | 2 | 2023 | 660 | 0.220 |
Why?
|
| Poloxamer | 1 | 2024 | 12 | 0.220 |
Why?
|
| Porosity | 1 | 2024 | 42 | 0.220 |
Why?
|
| Alginates | 1 | 2024 | 23 | 0.220 |
Why?
|
| Abortion, Induced | 1 | 2025 | 88 | 0.220 |
Why?
|
| Appendectomy | 1 | 2025 | 88 | 0.220 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2004 | 18 | 0.220 |
Why?
|
| Monitoring, Intraoperative | 1 | 2005 | 128 | 0.220 |
Why?
|
| Internship and Residency | 1 | 2015 | 1218 | 0.220 |
Why?
|
| Swine | 2 | 2025 | 1185 | 0.210 |
Why?
|
| Bronchi | 1 | 2005 | 97 | 0.210 |
Why?
|
| Lymphatic Abnormalities | 1 | 2024 | 35 | 0.210 |
Why?
|
| Organ Size | 5 | 2019 | 412 | 0.210 |
Why?
|
| Mice, Knockout | 4 | 2026 | 3822 | 0.210 |
Why?
|
| Health Services Needs and Demand | 1 | 2025 | 170 | 0.210 |
Why?
|
| Physician Assistants | 1 | 2025 | 81 | 0.210 |
Why?
|
| Adolescent | 11 | 2025 | 20706 | 0.210 |
Why?
|
| Specialties, Surgical | 1 | 2025 | 90 | 0.210 |
Why?
|
| Intraoperative Complications | 1 | 2005 | 154 | 0.210 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2022 | 177 | 0.210 |
Why?
|
| Predictive Value of Tests | 6 | 2021 | 2290 | 0.210 |
Why?
|
| Appendicitis | 1 | 2025 | 132 | 0.210 |
Why?
|
| Referral and Consultation | 2 | 2025 | 555 | 0.200 |
Why?
|
| Printing, Three-Dimensional | 1 | 2024 | 87 | 0.200 |
Why?
|
| Documentation | 1 | 2025 | 121 | 0.200 |
Why?
|
| LIM Domain Proteins | 1 | 2023 | 65 | 0.200 |
Why?
|
| Survival Rate | 6 | 2019 | 2120 | 0.200 |
Why?
|
| Mothers | 2 | 2023 | 374 | 0.200 |
Why?
|
| Amniotic Band Syndrome | 1 | 2003 | 25 | 0.190 |
Why?
|
| Colon | 1 | 2026 | 359 | 0.190 |
Why?
|
| Academic Success | 1 | 2023 | 22 | 0.190 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2024 | 128 | 0.190 |
Why?
|
| Biofilms | 2 | 2022 | 92 | 0.190 |
Why?
|
| Hysterotomy | 2 | 2021 | 135 | 0.190 |
Why?
|
| Inovirus | 1 | 2022 | 2 | 0.190 |
Why?
|
| Balloon Occlusion | 1 | 2022 | 47 | 0.190 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2024 | 344 | 0.190 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2024 | 253 | 0.190 |
Why?
|
| Hydronephrosis | 2 | 2013 | 34 | 0.180 |
Why?
|
| Limb Salvage | 1 | 2003 | 152 | 0.180 |
Why?
|
| Cohort Studies | 7 | 2021 | 5048 | 0.180 |
Why?
|
| Infant, Premature, Diseases | 1 | 2024 | 252 | 0.180 |
Why?
|
| Child, Preschool | 8 | 2025 | 14934 | 0.180 |
Why?
|
| Transduction, Genetic | 2 | 2013 | 277 | 0.180 |
Why?
|
| Neck | 2 | 2024 | 140 | 0.170 |
Why?
|
| Polyhydramnios | 1 | 2021 | 52 | 0.170 |
Why?
|
| Transforming Growth Factor beta | 1 | 2024 | 452 | 0.170 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 5 | 1 | 2021 | 4 | 0.170 |
Why?
|
| Cerebrospinal Fluid Leak | 2 | 2020 | 49 | 0.170 |
Why?
|
| Infant Mortality | 2 | 2020 | 181 | 0.170 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 4022 | 0.170 |
Why?
|
| Risk Assessment | 4 | 2022 | 3668 | 0.170 |
Why?
|
| Hemodynamics | 2 | 2022 | 805 | 0.170 |
Why?
|
| Surgical Wound | 1 | 2020 | 21 | 0.160 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2022 | 239 | 0.160 |
Why?
|
| Prognosis | 6 | 2024 | 4863 | 0.160 |
Why?
|
| Muscle Proteins | 1 | 2023 | 400 | 0.160 |
Why?
|
| Patient Selection | 2 | 2021 | 719 | 0.160 |
Why?
|
| Animals, Newborn | 1 | 2024 | 1015 | 0.160 |
Why?
|
| Ointments | 1 | 2020 | 13 | 0.160 |
Why?
|
| Wound Closure Techniques | 1 | 2020 | 25 | 0.160 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2023 | 584 | 0.160 |
Why?
|
| Adult | 16 | 2025 | 31107 | 0.160 |
Why?
|
| Adoptive Transfer | 1 | 2021 | 235 | 0.160 |
Why?
|
| Drug Delivery Systems | 1 | 2021 | 216 | 0.160 |
Why?
|
| Graft Rejection | 1 | 2024 | 558 | 0.160 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2020 | 19 | 0.160 |
Why?
|
| Immunohistochemistry | 4 | 2019 | 1596 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2025 | 499 | 0.160 |
Why?
|
| Neurosurgical Procedures | 2 | 2020 | 320 | 0.160 |
Why?
|
| Organ Specificity | 1 | 2021 | 396 | 0.160 |
Why?
|
| Multigene Family | 1 | 2021 | 289 | 0.160 |
Why?
|
| Diabetic Nephropathies | 1 | 2021 | 114 | 0.160 |
Why?
|
| Simulation Training | 1 | 2022 | 169 | 0.160 |
Why?
|
| Edema | 4 | 2023 | 133 | 0.160 |
Why?
|
| Cesarean Section | 1 | 2023 | 426 | 0.150 |
Why?
|
| Abdomen | 1 | 2020 | 128 | 0.150 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2021 | 146 | 0.150 |
Why?
|
| Pseudomonas Phages | 1 | 2019 | 11 | 0.150 |
Why?
|
| Haploinsufficiency | 1 | 2021 | 264 | 0.150 |
Why?
|
| Uterus | 1 | 2003 | 542 | 0.150 |
Why?
|
| Severity of Illness Index | 4 | 2025 | 3032 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 2060 | 0.140 |
Why?
|
| Bleomycin | 1 | 2019 | 116 | 0.140 |
Why?
|
| Infant, Premature | 1 | 2024 | 856 | 0.140 |
Why?
|
| Adaptation, Physiological | 2 | 2013 | 260 | 0.140 |
Why?
|
| Diabetes Mellitus | 2 | 2022 | 889 | 0.140 |
Why?
|
| Pregnancy Complications | 1 | 2023 | 540 | 0.140 |
Why?
|
| Hydrogels | 1 | 2019 | 91 | 0.140 |
Why?
|
| Gynecology | 1 | 2019 | 128 | 0.140 |
Why?
|
| Fetal Tissue Transplantation | 2 | 2011 | 14 | 0.140 |
Why?
|
| Regeneration | 1 | 2020 | 225 | 0.140 |
Why?
|
| Phagocytosis | 1 | 2019 | 188 | 0.140 |
Why?
|
| Estrogens | 1 | 2020 | 427 | 0.140 |
Why?
|
| Catheterization, Central Venous | 1 | 2019 | 134 | 0.130 |
Why?
|
| Meningomyelocele | 1 | 2021 | 269 | 0.130 |
Why?
|
| Oropharynx | 1 | 2017 | 31 | 0.130 |
Why?
|
| Time Factors | 3 | 2024 | 6194 | 0.130 |
Why?
|
| Chromosome Deletion | 1 | 2021 | 652 | 0.130 |
Why?
|
| Electronic Health Records | 1 | 2025 | 814 | 0.130 |
Why?
|
| Elective Surgical Procedures | 1 | 2018 | 162 | 0.130 |
Why?
|
| Texas | 5 | 2025 | 3638 | 0.130 |
Why?
|
| Liver | 4 | 2022 | 1788 | 0.130 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 163 | 0.130 |
Why?
|
| Heart Ventricles | 1 | 2022 | 759 | 0.130 |
Why?
|
| Financing, Government | 1 | 2017 | 33 | 0.130 |
Why?
|
| Depression | 2 | 2023 | 1315 | 0.130 |
Why?
|
| Insufflation | 1 | 2017 | 17 | 0.130 |
Why?
|
| Faculty, Medical | 1 | 2020 | 279 | 0.130 |
Why?
|
| Career Choice | 1 | 2019 | 167 | 0.130 |
Why?
|
| Disease Management | 1 | 2021 | 556 | 0.130 |
Why?
|
| Glycosaminoglycans | 2 | 2021 | 42 | 0.130 |
Why?
|
| Flow Cytometry | 3 | 2015 | 768 | 0.130 |
Why?
|
| Neural Tube Defects | 1 | 2020 | 337 | 0.130 |
Why?
|
| Ultrasonography | 3 | 2013 | 955 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 2 | 2025 | 2563 | 0.120 |
Why?
|
| Cell Proliferation | 3 | 2020 | 2460 | 0.120 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2016 | 45 | 0.120 |
Why?
|
| Transcriptome | 1 | 2023 | 1113 | 0.120 |
Why?
|
| Telemedicine | 1 | 2022 | 516 | 0.120 |
Why?
|
| Forecasting | 1 | 2017 | 350 | 0.120 |
Why?
|
| Carbon Dioxide | 1 | 2017 | 273 | 0.120 |
Why?
|
| Intestinal Obstruction | 1 | 2017 | 86 | 0.120 |
Why?
|
| Gastrointestinal Diseases | 1 | 2019 | 337 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 5171 | 0.110 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2013 | 56 | 0.110 |
Why?
|
| Survivors | 1 | 2018 | 344 | 0.110 |
Why?
|
| Hospital Charges | 2 | 2025 | 68 | 0.110 |
Why?
|
| Thoracic Cavity | 1 | 2014 | 2 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 704 | 0.110 |
Why?
|
| Biomarkers | 2 | 2015 | 3381 | 0.110 |
Why?
|
| Young Adult | 7 | 2023 | 9994 | 0.110 |
Why?
|
| Cell Nucleus | 2 | 2017 | 563 | 0.110 |
Why?
|
| Laparoscopy | 1 | 2020 | 541 | 0.110 |
Why?
|
| Rabbits | 1 | 2015 | 573 | 0.100 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2014 | 61 | 0.100 |
Why?
|
| Allergens | 1 | 2017 | 341 | 0.100 |
Why?
|
| In Vitro Techniques | 1 | 2015 | 808 | 0.100 |
Why?
|
| Octreotide | 1 | 2013 | 24 | 0.100 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 551 | 0.100 |
Why?
|
| Chimerism | 1 | 2013 | 29 | 0.100 |
Why?
|
| Probability | 2 | 2024 | 306 | 0.100 |
Why?
|
| Transplantation Chimera | 1 | 2013 | 45 | 0.100 |
Why?
|
| Submandibular Gland | 1 | 2013 | 5 | 0.100 |
Why?
|
| Chylothorax | 1 | 2013 | 26 | 0.100 |
Why?
|
| Interleukin-10 Receptor alpha Subunit | 1 | 2013 | 4 | 0.100 |
Why?
|
| Critical Illness | 1 | 2018 | 621 | 0.100 |
Why?
|
| Ovarian Diseases | 1 | 2013 | 23 | 0.100 |
Why?
|
| Spinal Dysraphism | 1 | 2017 | 277 | 0.100 |
Why?
|
| Torsion Abnormality | 1 | 2013 | 28 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2013 | 693 | 0.100 |
Why?
|
| Pleural Effusion | 1 | 2013 | 103 | 0.100 |
Why?
|
| Immunomodulation | 1 | 2013 | 84 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 2338 | 0.090 |
Why?
|
| Fetal Stem Cells | 1 | 2012 | 5 | 0.090 |
Why?
|
| Tumor Burden | 1 | 2013 | 235 | 0.090 |
Why?
|
| Growth Substances | 1 | 2012 | 99 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 4 | 2017 | 975 | 0.090 |
Why?
|
| Green Fluorescent Proteins | 1 | 2013 | 365 | 0.090 |
Why?
|
| Quality of Life | 2 | 2022 | 2078 | 0.090 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 222 | 0.090 |
Why?
|
| Embryo, Mammalian | 1 | 2013 | 403 | 0.090 |
Why?
|
| Intestinal Mucosa | 2 | 2026 | 760 | 0.090 |
Why?
|
| Mice, Inbred CFTR | 1 | 2011 | 3 | 0.080 |
Why?
|
| Counseling | 2 | 2023 | 237 | 0.080 |
Why?
|
| Cecal Diseases | 1 | 2010 | 5 | 0.080 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2011 | 39 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 228 | 0.080 |
Why?
|
| Appendix | 1 | 2010 | 11 | 0.080 |
Why?
|
| Hemangioblasts | 1 | 2010 | 2 | 0.080 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2010 | 14 | 0.080 |
Why?
|
| Immunity | 2 | 2022 | 179 | 0.080 |
Why?
|
| Chemokine CXCL12 | 1 | 2010 | 34 | 0.080 |
Why?
|
| Postnatal Care | 3 | 2019 | 51 | 0.080 |
Why?
|
| Fetal Death | 2 | 2013 | 114 | 0.080 |
Why?
|
| Analysis of Variance | 3 | 2010 | 937 | 0.080 |
Why?
|
| Ohio | 3 | 2014 | 85 | 0.080 |
Why?
|
| Quality of Health Care | 1 | 2013 | 408 | 0.080 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 3790 | 0.080 |
Why?
|
| Wounds, Penetrating | 1 | 2010 | 137 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2013 | 1575 | 0.080 |
Why?
|
| Abnormalities, Multiple | 1 | 2015 | 964 | 0.070 |
Why?
|
| Hyaluronan Receptors | 2 | 2021 | 64 | 0.070 |
Why?
|
| Urogenital Abnormalities | 1 | 2011 | 158 | 0.070 |
Why?
|
| Hernia, Umbilical | 1 | 2008 | 42 | 0.070 |
Why?
|
| Muscle, Skeletal | 1 | 2015 | 1000 | 0.070 |
Why?
|
| Apoptosis | 1 | 2015 | 1830 | 0.070 |
Why?
|
| Drainage | 1 | 2010 | 246 | 0.070 |
Why?
|
| Databases, Factual | 1 | 2013 | 1223 | 0.070 |
Why?
|
| Hernia, Diaphragmatic | 3 | 2013 | 91 | 0.070 |
Why?
|
| Neoplasms | 1 | 2022 | 2955 | 0.070 |
Why?
|
| Crohn Disease | 1 | 2010 | 287 | 0.070 |
Why?
|
| Salivary Glands | 1 | 2007 | 35 | 0.070 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2019 | 123 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 630 | 0.060 |
Why?
|
| Pregnancy Trimester, Second | 2 | 2019 | 160 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2021 | 299 | 0.060 |
Why?
|
| Ileum | 1 | 2007 | 109 | 0.060 |
Why?
|
| Dendritic Cells | 2 | 2021 | 437 | 0.060 |
Why?
|
| Physicians | 1 | 2013 | 634 | 0.060 |
Why?
|
| Shear Strength | 1 | 2026 | 17 | 0.060 |
Why?
|
| Snail Family Transcription Factors | 1 | 2026 | 27 | 0.060 |
Why?
|
| Pregnancy Outcome | 3 | 2017 | 615 | 0.060 |
Why?
|
| Adjuvants, Anesthesia | 1 | 2005 | 5 | 0.060 |
Why?
|
| Granulation Tissue | 1 | 2005 | 12 | 0.060 |
Why?
|
| Anesthesia, Epidural | 1 | 2005 | 20 | 0.060 |
Why?
|
| Vascular Remodeling | 1 | 2025 | 46 | 0.060 |
Why?
|
| Fetal Weight | 1 | 2025 | 67 | 0.060 |
Why?
|
| Parenteral Nutrition, Total | 2 | 2017 | 113 | 0.060 |
Why?
|
| Fentanyl | 1 | 2005 | 54 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2013 | 1267 | 0.050 |
Why?
|
| Streptozocin | 1 | 2004 | 26 | 0.050 |
Why?
|
| Sclerotherapy | 1 | 2024 | 36 | 0.050 |
Why?
|
| Incidence | 3 | 2019 | 3315 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2025 | 247 | 0.050 |
Why?
|
| Airway Management | 1 | 2024 | 67 | 0.050 |
Why?
|
| Surface-Active Agents | 1 | 2024 | 30 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 206 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2005 | 356 | 0.050 |
Why?
|
| Mice, Inbred NOD | 1 | 2004 | 301 | 0.050 |
Why?
|
| Mice, Mutant Strains | 2 | 2019 | 355 | 0.050 |
Why?
|
| Lentivirus | 1 | 2004 | 81 | 0.050 |
Why?
|
| Models, Animal | 2 | 2020 | 450 | 0.050 |
Why?
|
| Wrist | 1 | 2003 | 27 | 0.050 |
Why?
|
| Sirolimus | 1 | 2024 | 231 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2005 | 333 | 0.050 |
Why?
|
| Cell Separation | 1 | 2023 | 220 | 0.050 |
Why?
|
| Universities | 1 | 2023 | 127 | 0.050 |
Why?
|
| Sildenafil Citrate | 1 | 2022 | 56 | 0.050 |
Why?
|
| Operative Time | 1 | 2023 | 200 | 0.050 |
Why?
|
| Pseudomonas | 1 | 2022 | 15 | 0.050 |
Why?
|
| Culture Media, Conditioned | 1 | 2022 | 82 | 0.050 |
Why?
|
| Computer Simulation | 1 | 2025 | 671 | 0.050 |
Why?
|
| Propylene Glycol | 1 | 2021 | 8 | 0.050 |
Why?
|
| Antithrombin III | 1 | 2021 | 23 | 0.040 |
Why?
|
| Surgical Procedures, Operative | 1 | 2024 | 223 | 0.040 |
Why?
|
| Administration, Cutaneous | 1 | 2021 | 63 | 0.040 |
Why?
|
| Intraepithelial Lymphocytes | 1 | 2021 | 6 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 2090 | 0.040 |
Why?
|
| Disaccharides | 1 | 2021 | 19 | 0.040 |
Why?
|
| Dilatation | 1 | 2022 | 65 | 0.040 |
Why?
|
| Dilatation, Pathologic | 1 | 2021 | 75 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2025 | 433 | 0.040 |
Why?
|
| Intubation, Intratracheal | 1 | 2024 | 286 | 0.040 |
Why?
|
| Thorax | 1 | 2021 | 65 | 0.040 |
Why?
|
| Social Class | 1 | 2023 | 209 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2022 | 222 | 0.040 |
Why?
|
| Mast Cells | 1 | 2021 | 66 | 0.040 |
Why?
|
| Mammals | 1 | 2022 | 252 | 0.040 |
Why?
|
| Immune System | 1 | 2021 | 99 | 0.040 |
Why?
|
| Water | 1 | 2021 | 185 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 102 | 0.040 |
Why?
|
| Patient Preference | 1 | 2022 | 150 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2022 | 6439 | 0.040 |
Why?
|
| Diaphragm | 1 | 2021 | 100 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2021 | 382 | 0.040 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2021 | 78 | 0.040 |
Why?
|
| Heparin | 1 | 2021 | 203 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2023 | 469 | 0.040 |
Why?
|
| Ethanol | 1 | 2021 | 165 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2022 | 393 | 0.040 |
Why?
|
| Immunocompetence | 1 | 2019 | 31 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2022 | 302 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2022 | 465 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2023 | 700 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2024 | 1058 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 226 | 0.040 |
Why?
|
| Toll-Like Receptor 3 | 1 | 2019 | 20 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2024 | 511 | 0.040 |
Why?
|
| Resuscitation | 1 | 2022 | 275 | 0.040 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2019 | 49 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2021 | 408 | 0.040 |
Why?
|
| Middle Aged | 2 | 2021 | 28352 | 0.040 |
Why?
|
| Central Venous Catheters | 1 | 2019 | 48 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 510 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2013 | 1484 | 0.040 |
Why?
|
| Kinetics | 1 | 2020 | 1087 | 0.040 |
Why?
|
| Longitudinal Studies | 2 | 2015 | 1486 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2019 | 413 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 694 | 0.030 |
Why?
|
| Interferons | 1 | 2019 | 135 | 0.030 |
Why?
|
| Hemorrhage | 1 | 2021 | 490 | 0.030 |
Why?
|
| Decision Making | 1 | 2023 | 696 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 706 | 0.030 |
Why?
|
| Psychometrics | 1 | 2022 | 672 | 0.030 |
Why?
|
| Age Factors | 2 | 2018 | 2825 | 0.030 |
Why?
|
| Hydrocephalus | 1 | 2020 | 275 | 0.030 |
Why?
|
| Endoscopy | 1 | 2019 | 267 | 0.030 |
Why?
|
| Aortic Valve | 1 | 2021 | 451 | 0.030 |
Why?
|
| Recurrence | 1 | 2021 | 1469 | 0.030 |
Why?
|
| Perinatal Mortality | 1 | 2017 | 44 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 657 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2020 | 426 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2019 | 238 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2021 | 602 | 0.030 |
Why?
|
| Comparative Effectiveness Research | 1 | 2017 | 70 | 0.030 |
Why?
|
| Cross-Linking Reagents | 1 | 2017 | 49 | 0.030 |
Why?
|
| Sulfhydryl Compounds | 1 | 2017 | 54 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2019 | 359 | 0.030 |
Why?
|
| Hospitalization | 1 | 2025 | 1926 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 636 | 0.030 |
Why?
|
| Half-Life | 1 | 2016 | 148 | 0.030 |
Why?
|
| Biological Availability | 1 | 2016 | 138 | 0.030 |
Why?
|
| Stents | 1 | 2022 | 778 | 0.030 |
Why?
|
| Protein Transport | 1 | 2017 | 366 | 0.030 |
Why?
|
| Immunization | 1 | 2017 | 267 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2017 | 242 | 0.030 |
Why?
|
| Phenotype | 1 | 2025 | 4465 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2017 | 1920 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2022 | 2890 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2017 | 442 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 707 | 0.030 |
Why?
|
| Graft vs Host Reaction | 1 | 2013 | 11 | 0.030 |
Why?
|
| Drug Evaluation | 1 | 2013 | 101 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2004 | 1443 | 0.030 |
Why?
|
| Thoracostomy | 1 | 2013 | 26 | 0.030 |
Why?
|
| Chest Tubes | 1 | 2013 | 38 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2021 | 948 | 0.030 |
Why?
|
| Cardiac Output, High | 1 | 2013 | 2 | 0.030 |
Why?
|
| Pneumonia | 1 | 2017 | 339 | 0.020 |
Why?
|
| Nausea | 1 | 2013 | 83 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2013 | 110 | 0.020 |
Why?
|
| ROC Curve | 1 | 2014 | 608 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2019 | 1169 | 0.020 |
Why?
|
| Vomiting | 1 | 2013 | 104 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 2013 | 107 | 0.020 |
Why?
|
| Risk Factors | 2 | 2019 | 10939 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 2330 | 0.020 |
Why?
|
| Tidal Volume | 1 | 2011 | 42 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2013 | 352 | 0.020 |
Why?
|
| Radiography | 1 | 2013 | 741 | 0.020 |
Why?
|
| Urinary Tract | 1 | 2011 | 54 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2013 | 315 | 0.020 |
Why?
|
| Benzylamines | 1 | 2010 | 22 | 0.020 |
Why?
|
| Ovary | 1 | 2013 | 351 | 0.020 |
Why?
|
| Heterocyclic Compounds | 1 | 2010 | 17 | 0.020 |
Why?
|
| Hospital Records | 1 | 2010 | 8 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1223 | 0.020 |
Why?
|
| Soft Tissue Injuries | 1 | 2010 | 10 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2010 | 263 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2010 | 69 | 0.020 |
Why?
|
| Dermatologic Surgical Procedures | 1 | 2010 | 34 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2010 | 74 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 425 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2010 | 277 | 0.020 |
Why?
|
| Soft Tissue Infections | 1 | 2010 | 89 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2010 | 182 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 648 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 2195 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 1208 | 0.020 |
Why?
|
| Microvilli | 1 | 2007 | 62 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2007 | 234 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2007 | 115 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2007 | 271 | 0.020 |
Why?
|
| Transgenes | 1 | 2007 | 320 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 1147 | 0.020 |
Why?
|
| Enteral Nutrition | 1 | 2008 | 282 | 0.020 |
Why?
|
| Comorbidity | 1 | 2011 | 1582 | 0.010 |
Why?
|
| Syndrome | 1 | 2008 | 1159 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2008 | 505 | 0.010 |
Why?
|
| Tobramycin | 1 | 2005 | 22 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 1367 | 0.010 |
Why?
|
| Bupivacaine | 1 | 2005 | 26 | 0.010 |
Why?
|
| Administration, Topical | 1 | 2005 | 134 | 0.010 |
Why?
|
| Ciprofloxacin | 1 | 2005 | 62 | 0.010 |
Why?
|
| Aged | 1 | 2003 | 20857 | 0.010 |
Why?
|
| Thoracotomy | 1 | 2005 | 107 | 0.010 |
Why?
|
| Anesthetics, Local | 1 | 2005 | 85 | 0.010 |
Why?
|
| Analgesics | 1 | 2005 | 119 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2010 | 2556 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 2005 | 212 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2005 | 271 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2005 | 250 | 0.010 |
Why?
|
| Pain | 1 | 2005 | 428 | 0.010 |
Why?
|